SCHEMBL21247382

SCHEMBL21247382

CC1(C)CCc2sc(NC(=O)c3ccccc3)c(C(=O)O)c2C1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB7A P51149 3/20 0.80
▸ MEN1 O00255 10/20 0.67
▸ KMT2A Q03164 10/20 0.67
▸ MAPT P10636 7/20 0.67
▸ RAB9A P51151 6/20 0.67
▸ NPC1 O15118 5/20 0.67
▸ SMN1; SMN2 Q16637 3/20 0.67
▸ ALDH1A1 P00352 3/20 0.67
▸ KDM4E B2RXH2 2/20 0.67
▸ LMNA P02545 1/20 0.66
▸ POLB P06746 1/20 0.66
▸ HPGD P15428 1/20 0.66
▸ ESR2 Q92731 1/20 0.66
▸ CTDSP1 Q9GZU7 1/20 0.66
▸ TDP1 Q9NUW8 1/20 0.66
▸ TP53 P04637 1/20 0.55
▸ PLA2G1B P04054 1/20 0.54
▸ GAA P10253 1/20 0.54
▸ CDC42 P60953 1/20 0.54
▸ RAB2A P61019 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21247392 0.92 RAB7A (0.68) RAB7AMEN1KMT2AMAPTRAB9A
SCHEMBL21247202 0.90 TNF (0.68) RAB7AMEN1KMT2AMAPTRAB9A
SCHEMBL19321160 0.86 RAB7A (0.62) RAB7AMEN1KMT2AMAPTRAB9A
SCHEMBL21261032 0.85 RAB7A (0.60) RAB7AMEN1KMT2AMAPTRAB9A
SCHEMBL19325776 0.85 RAB7A (0.61) RAB7AMEN1KMT2AMAPTRAB9A
SCHEMBL19321159 0.85 RAB7A (0.60) RAB7AMEN1KMT2AMAPTRAB9A
SCHEMBL19325973 0.84 RAB7A (0.59) RAB7AMEN1KMT2AMAPTRAB9A
SCHEMBL21247252 0.83 RAB7A (0.59) RAB7AMEN1KMT2AMAPTRAB9A
SCHEMBL19140455 0.83 RAB7A (0.61) RAB7AMEN1KMT2AMAPTRAB9A
SCHEMBL21247188 0.83 NOD1 (0.71) RAB7AMEN1KMT2AMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11492347-B2 Fused thiophene derivatives and their uses ENYO PHARMA (FR) 2022-11-08 — — US disclosed
EP-3749659-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO Pharma (FR) 2020-12-16 — — EP disclosed
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-19 — — US disclosed
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-19 — — US disclosed
WO-2019154950-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 — — WO disclosed
WO-2019154950-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES FTH1, SLC40A1, FECH RAB7A 2283/4885MEN1 3538/4885KMT2A 3454/4885
US-11492347-B2 Fused thiophene derivatives and their uses FTH1, SLC40A1, FECH RAB7A 2283/4885MEN1 3538/4885KMT2A 3454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback